104
Participants
Start Date
October 6, 2016
Primary Completion Date
October 23, 2020
Study Completion Date
October 23, 2020
Caplacizumab
Standard of Care
• PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab).
Investigator site, Valhalla
Investigator site, Pittsburgh
Investigator Site, Durham
Investigator site, Greenville
Investigator Site, Charleston
Investigator Site, Columbus
Investigator site, St Louis
Investigator Site, Oklahoma City
Investigator site, Vienna
Investigator site, Antwerp
Investigator site, Brussels
Investigator site, La Louvière
Investigator site, Leuven
Investigator Site, Halifax
Investigator Site, Québec
Investigator Site, Toronto
Investigator Site, Brno
Investigator Site, Olomouc
Investigator site, Caen
Investigator site, Lille
Investigator site, Marseille
Investigator site 1, Paris
Investigator site 2, Paris
Investigator Site, Budapest
Investigator Site, Debrecen
Investigator Site, Haifa
Investigator Site, Jerusalem Region
Investigator Site, Nahariya
Investigator Site, Catania
Investigator Site, Milan
Investigator site, Pesaro
Investigator Site, Rome
Investigator Site, Vicenza
Investigator Site 1, Barcelona
Investigator Site 2, Barcelona
Investigator site, Seville
Investigator Site 2, Valencia
Investyigator Site 1, Valencia
Investigator site, Bern
Investigator site, Ankara
Investigator site, Istanbul
Investigator site, Kayseri
Investigator Site, Bristol
Investigator site, Liverpool
Investigator Site, London
Lead Sponsor
Sanofi
INDUSTRY